Natixis Castle Biosciences Inc Transaction History
Natixis
- $16 Billion
- Q4 2024
A detailed history of Natixis transactions in Castle Biosciences Inc stock. As of the latest transaction made, Natixis holds 19,600 shares of CSTL stock, worth $393,960. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,600Holding current value
$393,960% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CSTL
# of Institutions
209Shares Held
25.9MCall Options Held
128KPut Options Held
35.4K-
Black Rock Inc. New York, NY3.04MShares$61.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.83MShares$36.8 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.8MShares$36.1 Million0.24% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.44MShares$28.9 Million0.02% of portfolio
-
Dimensional Fund Advisors LP Austin, TX999KShares$20.1 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $529M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...